JPMorgan maintains BridgeBio Pharma at 'overweight' with a price target of $38.00

  • Investing.com
JPMorgan maintains BridgeBio Pharma at 'overweight' with a price target of $38.00

An analyst from JPMorgan maintained BridgeBio Pharma (NASDAQ: BBIO ) at 'overweight' with a price target of $38.00 from a prior price target of %currency%%price%.

Prior to this rating, BridgeBio Pharma had 10 buy ratings, 1 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on BridgeBio Pharma, click here. For more news on BridgeBio Pharma, click here.

BridgeBio Pharma's stock price closed at $29.80. They are down -13.52% in the last month and up 178.50% in the last 12 months.

According to Investing Pro, BridgeBio Pharma's fair value is $26.46, a downside of 11.19%. BridgeBio Pharma's fair value comes with a high degree of uncertainty, according to InvestingPro.

Check out BridgeBio Pharma's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles